Product Description
Mechanisms of Action: DR Antagonist,ADR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bulgaria | Czech | Denmark | Estonia | Finland | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Russia | Saudi Arabia | Slovakia | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: University Medical Center Groningen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Schizophrenia
Phase 3: Schizophrenia|Tic Disorders|Dementia|Depressive Disorder|Psychophysiologic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAILOR | P4 |
Terminated |
Schizophrenia |
2027-03-03 |
|
BAR-MEDS Chlorprothixene | N/A |
Recruiting |
Obesity, Morbid |
2026-12-01 |
|
HAMLETT | P4 |
Active, not recruiting |
Schizophrenia |
2021-02-04 |
|
GAP | P3 |
Terminated |
Depressive Disorder|Dementia|Psychophysiologic Disorders|Tic Disorders|Schizophrenia |
2017-06-28 |